Mention executive pay in the pharmaceutical industry and the biggest players often come to mind. But what about the next tier of specialty drug makers? What does compensation look like for those executives and how are those compensation packages decided?. In a new analysis, Sanford Bernstein analyst Ronny Gal examined data from proxy statements filed between 2010 and 2013 by seven drug makers – Actavis, Allergan, Hospira, Momenta Pharmaceuticals, Mylan Laboratories, Teva Pharmaceuticals and Theravance – for clues to understanding compensation decisions and the basis for making meaningful comparisons.